Product
Ramucirumab
Aliases
anti-VEGFR-2 fully human monoclonal antibody IMC-1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, CYRAMZA®, IMC-1121B (3 other aliases)
Name
CYRAMZA
FDA Approved
Yes
60 clinical trials
1 organization
1 drug
1 abstract
110 indications
1 document
Indication
Colorectal CancerIndication
Gastroesophageal CancerIndication
Renal Cell CarcinomaIndication
Solid TumorIndication
CholangiocarcinomaIndication
Bladder CancerIndication
Ovarian CancerIndication
Stomach CancerIndication
Palpable Subcutaneous Malignant LesionsIndication
MelanomaIndication
Primary Peritoneal CancerIndication
Fallopian tube cancerIndication
Advanced or Metastatic Solid TumorIndication
Pancreatic Ductal AdenocarcinomaIndication
Lung CancerIndication
Alveolar Soft Part SarcomaIndication
Pancreatic CancerIndication
Breast CancerIndication
AdenocarcinomaIndication
Esophageal CancerIndication
Gastroesophageal JunctionIndication
Gastroesophageal adenocarcinomaIndication
Esophageal NeoplasmsIndication
Esophageal cancerIndication
CancerIndication
PediatricIndication
AdolescentIndication
Gastric AdenocarcinomaIndication
Stomach AdenocarcinomaIndication
Hepatocellular CarcinomaIndication
Synovial SarcomaIndication
HealthyIndication
Advanced Solid TumorIndication
Metastatic Non-Small Lung Cell CancerIndication
Recurrent Non-Small Cell Lung CancerIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
Gastroesophageal Junction AdenocarcinomaIndication
EGFR gene mutationIndication
Advanced CancerIndication
Metastatic CancerIndication
Recurrent head and neck cancerIndication
Head and Neck Squamous Cell CarcinomaIndication
Recurrent Head and Neck CarcinomaIndication
Metastatic Head and Neck CancerIndication
HNSCCIndication
MesotheliomaIndication
malignantIndication
Gastric Esophageal CancerIndication
Advanced Hepatocellular CarcinomaIndication
Esophageal CarcinomaIndication
Metastatic Esophageal CancerIndication
Esophageal AdenocarcinomaIndication
Stage III Gastric CancerIndication
Stage IV Gastric CancerIndication
Gastric Cancer AJCC v8Indication
Recurrent Lung Non-Small Cell CarcinomaIndication
Stage III Gastric Cancer AJCC v8Indication
Stage IIIA Gastric Cancer AJCC v8Indication
Gastric Cancer, Stage IIIC, AJCC v8Indication
Stage IV Gastric Cancer AJCC v8Indication
Thymic CarcinomaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Carcinoid TumorsIndication
Stomach NeoplasmIndication
Small Intestinal AdenocarcinomaIndication
Small Intestinal Adenocarcinoma AJCC v8Indication
Advanced Gastric or EGJ CancerIndication
MetastaticIndication
RecurrentIndication
NSCLCIndication
Bile Duct CancerIndication
Esophageal carcinomaIndication
Recurrent Gastric CarcinomaIndication
Esophageal Cancer, Stage III, AJCC v7Indication
Second LineIndication
ChemotherapyIndication
Pancreatic adenocarcinomaIndication
Gallbladder Cancer Stage III AJCC v7Indication
Gallbladder Cancer, Stage IIIA AJCC v7Indication
Stage IIIB Gallbladder Cancer AJCC v7Indication
Gallbladder CancerIndication
Gallbladder Cancer AJCC v7Indication
Intrahepatic CholangiocarcinomaIndication
Gallbladder CarcinomaIndication
Lung Non-Small Cell CarcinomaIndication
Stage III Lung Cancer AJCC v8Indication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
Desmoplastic Small Round Cell TumorIndication
Esophageal Adenocarcinoma AJCC v8Indication
Gastric CancerIndication
ThymomaDrug
TiragolumabClinical trial
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2019-01-23
Clinical trial
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2023-03-01
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Platform Study of AB122 Based Treatments in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI TherapyStatus: Completed, Estimated PCD: 2017-10-19
Clinical trial
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)Status: Active (not recruiting), Estimated PCD: 2020-05-22
Clinical trial
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06DStatus: Not yet recruiting, Estimated PCD: 2026-12-28
Clinical trial
CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric ResearchStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)Status: Active (not recruiting), Estimated PCD: 2024-08-24
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerStatus: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-23
Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With SorafenibStatus: Completed, Estimated PCD: 2018-03-15
Clinical trial
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial SarcomaStatus: Terminated, Estimated PCD: 2023-02-23
Clinical trial
A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of RamucirumabStatus: Completed, Estimated PCD: 2021-05-09
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based TherapyStatus: Completed, Estimated PCD: 2017-04-21
Clinical trial
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2021-05-25
Clinical trial
A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)Status: Terminated, Estimated PCD: 2023-02-12
Clinical trial
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceStatus:
Clinical trial
A Phase 2, Open-label, Randomized, Multi-arm Study of BGB-A445 in Combination With Investigational Agents in Non-Small Cell Lung Cancer Patients Previously Treated With Anti-PD-(L)1 AntibodyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung CarcinomaStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaStatus: Completed, Estimated PCD: 2023-04-14
Clinical trial
An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor (TKI)-naïve Epidermal Growth Factor Receptor (EGFR)-Mutant Locally Advanced or Metastatic NSCLCStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)Status: Recruiting, Estimated PCD: 2028-04-30
Clinical trial
Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299Status: Terminated, Estimated PCD: 2022-05-11
Clinical trial
Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or PembrolizumabStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-11
Clinical trial
An Open, Single-arm, Single-centre,Phase II Clinical Study Evaluating Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 StudyStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-03-15
Clinical trial
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)Status: Active (not recruiting), Estimated PCD: 2022-04-14
Clinical trial
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-01-19
Clinical trial
An Investigator-Sponsored Phase 2 Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-08-19
Clinical trial
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)Status: Not yet recruiting, Estimated PCD: 2028-05-31
Clinical trial
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy - The Phase II/III RAMIRIS StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung CancersStatus: Recruiting, Estimated PCD: 2028-08-17
Clinical trial
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)Status: Completed, Estimated PCD: 2021-07-16
Clinical trial
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract CancerStatus: Active (not recruiting), Estimated PCD: 2018-02-16
Clinical trial
A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).Status: Not yet recruiting, Estimated PCD: 2025-08-31
Clinical trial
Phase Ib-II Study of Ramucirumab Combined With Standard Nab-paclitaxel and Gemcitabine as First-line Treatment in Patients With Advanced Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-06-17
Clinical trial
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary CancersStatus: Completed, Estimated PCD: 2022-06-29
Clinical trial
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLCStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
A Phase III Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)Status: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based TherapyStatus: Completed, Estimated PCD: 2022-01-13
Clinical trial
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell TumorStatus: Active (not recruiting), Estimated PCD: 2024-06-11
Clinical trial
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)Status: Active (not recruiting), Estimated PCD: 2022-10-19
Clinical trial
Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative EffortStatus: Active (not recruiting), Estimated PCD: 2021-10-09
Document
DailyMed Label: CYRAMZAOrganization
Eli Lilly and Company